Angela Yen Moore1,2,3,4,5,6,7, Edward L Lain1,2,3,4,5,6,7, Amy McMichael1,2,3,4,5,6,7, Leon Kircik1,2,3,4,5,6,7, Andrea L Zaenglein1,2,3,4,5,6,7, Adelaide A Hebert1,2,3,4,5,6,7, Ayman Grada1,2,3,4,5,6,7. 1. Dr. Moore is with Arlington Center for Dermatology and Arlington Research Center in Arlington, Texas and Baylor University Medical Center in Dallas, Texas. 2. Dr. Lain is with the Austin Institute for Clinical Research in Pflugerville, Texas. 3. Dr. McMichael is with Wake Forest Baptist Health in Winston-Salem, North Carolina. 4. Dr. Kircik is with Icahn School of Medicine at Mount Sinai in New York, New York. 5. Dr. Grada is with Almirall, LLC in Exton, Pennsylvania. 6. Dr. Zaenglein is with Penn State/Hershey Medical Center in Hershey, Pennsylvania. 7. Dr. Hebert is with UTHealth McGovern Medical School in Houston, Texas.
Abstract
CLINICAL TRIALS ID: NCT02959970 BACKGROUND: Acne vulgaris in patients aged younger than 12 years is increasingly common and primarily noninflammatory (i.e., comedonal). Dapsone 7.5% gel is indicated for the topical treatment of acne vulgaris in patients nine years of age or older. OBJECTIVE: We sought to evaluate efficacy, safety, tolerability, and pharmacokinetics (PK) of once-daily topical dapsone 7.5% gel. METHODS: This was a Phase IV, multicenter, open-label study in patients with acne aged 9 to 11 years. Patients applied dapsone 7.5% gel once daily to the face and acne-affected areas on the upper chest, upper back, and shoulders for 12 weeks. Patients in the PK cohort applied dapsone 7.5% gel under maximal-use conditions for eight days and a thin layer for the remaining 11 weeks. Lesion counts and proportions of patients with an Investigator's Global Assessment score of zero points (clear) or one point (almost clear) were assessed. Plasma concentrations of dapsone and metabolites were evaluated after one week in the PK cohort. Safety and dermal tolerability were evaluated. RESULTS: After 12 weeks, facial acne was clear or almost clear in about 47 percent of patients. Inflammatory, noninflammatory, and total lesions decreased from baseline, with a greater reduction apparent in noninflammatory lesions. Systemic exposure to dapsone in PK patients was low. The overall rate of adverse events was low, and dermal tolerability scores indicated no or mild stinging/burning, dryness, scaling, and erythema. CONCLUSION: Once-daily topical dapsone 7.5% gel used for 12 weeks was safe, effective, and well tolerated in preadolescent patients with acne.
CLINICAL TRIALS ID: NCT02959970 BACKGROUND:Acne vulgaris in patients aged younger than 12 years is increasingly common and primarily noninflammatory (i.e., comedonal). Dapsone 7.5% gel is indicated for the topical treatment of acne vulgaris in patients nine years of age or older. OBJECTIVE: We sought to evaluate efficacy, safety, tolerability, and pharmacokinetics (PK) of once-daily topical dapsone 7.5% gel. METHODS: This was a Phase IV, multicenter, open-label study in patients with acne aged 9 to 11 years. Patients applied dapsone 7.5% gel once daily to the face and acne-affected areas on the upper chest, upper back, and shoulders for 12 weeks. Patients in the PK cohort applied dapsone 7.5% gel under maximal-use conditions for eight days and a thin layer for the remaining 11 weeks. Lesion counts and proportions of patients with an Investigator's Global Assessment score of zero points (clear) or one point (almost clear) were assessed. Plasma concentrations of dapsone and metabolites were evaluated after one week in the PK cohort. Safety and dermal tolerability were evaluated. RESULTS: After 12 weeks, facial acne was clear or almost clear in about 47 percent of patients. Inflammatory, noninflammatory, and total lesions decreased from baseline, with a greater reduction apparent in noninflammatory lesions. Systemic exposure to dapsone in PK patients was low. The overall rate of adverse events was low, and dermal tolerability scores indicated no or mild stinging/burning, dryness, scaling, and erythema. CONCLUSION: Once-daily topical dapsone 7.5% gel used for 12 weeks was safe, effective, and well tolerated in preadolescent patients with acne.
Authors: Zoe D Draelos; Eric Carter; J Michael Maloney; Boni Elewski; Yves Poulin; Charles Lynde; Steven Garrett Journal: J Am Acad Dermatol Date: 2007-01-17 Impact factor: 11.527
Authors: Sheila Fallon Friedlander; Hilary E Baldwin; Anthony J Mancini; Albert C Yan; Lawrence F Eichenfield Journal: Semin Cutan Med Surg Date: 2011-09
Authors: Diane M Thiboutot; Leon Kircik; Amy McMichael; Fran E Cook-Bolden; Stephen K Tyring; David R Berk; Joan-En Chang-Lin; Vince Lin; Alexandre Kaoukhov Journal: J Clin Aesthet Dermatol Date: 2016-10-01
Authors: Lawrence F Eichenfield; Ted Lain; Ellen H Frankel; Terry M Jones; Joan-En Chang-Lin; David R Berk; Shiling Ruan; Alexandre Kaoukhov Journal: J Drugs Dermatol Date: 2016-08-01 Impact factor: 2.114
Authors: Jamie L Goldberg; Tushar S Dabade; Scott A Davis; Steven R Feldman; Daniel P Krowchuk; Alan B Fleischer Journal: Pediatr Dermatol Date: 2011 Nov-Dec Impact factor: 1.588
Authors: Scott A Davis; Laura F Sandoval; Cheryl J Gustafson; Steven R Feldman; Kelly M Cordoro Journal: Pediatr Dermatol Date: 2013-07-22 Impact factor: 1.588